



ImmunOs Therapeutics AG appoints Pamela Carroll, Ph.D., a Leading Industry and Academic Oncology Drug Discovery Expert to the Scientific Advisory Board

Schlieren (Zurich Area), Switzerland. – October 30, 2017 – ImmunOs Therapeutics AG, a Swiss biotechnology company leading the next generation of innate and adaptive immunity focused immunotherapies for cancer, today announced the appointment of Pamela Carroll, Ph.D. to its scientific advisory board.

Pamela Carroll is currently the Senior Vice President, Immuno-oncology at Genocera Biosciences in Cambridge, Massachusetts. Pamela experience includes distinguished work in both academia and industry. She was the former Vice President of Drug Discovery at Roche and Vice President of Janssen Oncology, Johnson and Johnson Innovation, Senior Vice President of research at Compass Therapeutics, a \$170M series A immuno-oncology biologics company, founding Head of Research at the Belfer Institute for Applied Cancer Science at Dana Farber Cancer Institute, Harvard Medical School, and Department Head of Cancer Pathways at Merck Research Laboratories.

“Pamela brings exceptional knowledge and experience to our scientific advisory team. Her global experience in industry and academia will be a valuable asset as we initiate new clinical planning and accelerate development of our lead candidate forward through new partnerships with leading biopharma companies and scientist worldwide. We are honored that Pamela has joined our team,” said Sean R. Smith, Chief Executive Officer at ImmunOs Therapeutics AG

About ImmunOs Therapeutics AG:

ImmunOs Therapeutics AG is a biotechnology company focused on discovering and developing the next generation of novel human immunomodulatory proteins focused in innate and adaptive immunity. Our mission is to develop novel therapeutics that will improve the lives of patients with serious disease.

ImmunOs Therapeutics AG lead program is a next generation, novel platform of targets that differ from the common competitor antibodies as they target diverse immunoregulatory receptors using one molecule to create a synergistic response between immune cells that activate anti-tumor responses built upon years of research and development. ImmunOs Proteins work directly on the Innate Immune System (Macrophages and NK Cells) and Indirectly on the Adaptive Immune System by targeting MDSCs and thus allowing the expansion of T cells leading to a strong anti-tumor response in combination with checkpoint inhibitors (CTLA-4, PD-1, PD-L1) and costimulatory agonists (e.g. 4-1BB) in multiple cancer indications. For more information, please visit www.immunotherapeutics.com.



Contact:

Investor Relations

Wagistrasse 14

8952 Schlieren (Zurich Area)

info@immunotherapeutics.com